Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy:
Heart and Estrogen/Progestin Replacement Study Follow-up (HERS
Context: The Heart and Estrogen/progestin Replacement Study (HERS)
found no overall reduction in risk of coronary heart disease
(CHD) events among postmenopausal women with CHD.
the hormone group, findings did suggest a higher risk of CHD
events during the first year, and a decreased risk during years
3 to 5.
Objective: To determine if the risk reduction observed in
the later years of HERS persisted and resulted in an overall
reduced risk of CHD events with additional years of follow-up.
Conclusions: Lower rates of CHD events among women in the hormone
group in the final years of HERS did not persist during additional
years of follow-up.
After 6.8 years, hormone therapy did not
reduce risk of cardiovascular events in women with CHD.
Postmenopausal hormone therapy should not be used to reduce
risk for CHD events in women with CHD.
[07/03/2002; Journal of the AMA (Free Registration Required)]
New York Times, 7/10/02
Cancer Causes & Control, 10/02
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.